Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. boosted its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 236.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 81,262 shares of the biopharmaceutical company's stock after purchasing an additional 57,086 shares during the quarter. Bristol-Myers Squibb makes up approximately 1.2% of Point72 Asia Singapore Pte. Ltd.'s investment portfolio, making the stock its 13th largest holding. Point72 Asia Singapore Pte. Ltd.'s holdings in Bristol-Myers Squibb were worth $4,596,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Fiduciary Alliance LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $253,000. Wedmont Private Capital increased its holdings in shares of Bristol-Myers Squibb by 29.5% during the fourth quarter. Wedmont Private Capital now owns 10,487 shares of the biopharmaceutical company's stock valued at $586,000 after acquiring an additional 2,392 shares in the last quarter. BCS Wealth Management acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $329,000. Rosenberg Matthew Hamilton increased its holdings in shares of Bristol-Myers Squibb by 68.6% during the fourth quarter. Rosenberg Matthew Hamilton now owns 1,705 shares of the biopharmaceutical company's stock valued at $96,000 after acquiring an additional 694 shares in the last quarter. Finally, 626 Financial LLC increased its holdings in shares of Bristol-Myers Squibb by 7.5% during the fourth quarter. 626 Financial LLC now owns 10,053 shares of the biopharmaceutical company's stock valued at $569,000 after acquiring an additional 699 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.09% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on BMY. Piper Sandler began coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Citigroup upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. UBS Group dropped their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded up $0.96 during midday trading on Friday, reaching $46.77. 12,103,063 shares of the company's stock traded hands, compared to its average volume of 13,232,604. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a market cap of $95.18 billion, a P/E ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a fifty day simple moving average of $53.05 and a two-hundred day simple moving average of $55.99.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the prior year, the company earned ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.30%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.